» Articles » PMID: 24615647

Is Carcinoma in Situ a Precursor Lesion of Invasive Breast Cancer?

Overview
Journal Int J Cancer
Specialty Oncology
Date 2014 Mar 12
PMID 24615647
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

This study measures the probability of development of invasive breast cancer (BC) following the diagnosis of carcinomas in situ (CIS). A 25-year prospective follow-up was conducted by linking the Canadian National Breast Screening Study (CNBSS) to cancer registries and a national vital statistics database. Subsequent BC incidence was identified in CNBSS women who were diagnosed with CIS. CIS was classified into ductal (DCIS) and lobular carcinoma in situ (LCIS). Cumulative cancer incidence probabilities were calculated and a 1:5 matched nested case control study was conducted to estimate the odds of BC development. Of the 146 women diagnosed with CIS, 26 developed invasive BC (17.8%) and 12 died of BC (8.2%). The average time from the diagnosis of CIS to invasive BC was 6.3 years (± 5.6). The 20-year cumulative incidence probabilities for DCIS and LCIS were 19.0% (95%CI: 11.2, 26.8) and 21.3% (95%CI: 7.1, 35.4) respectively. The odds of development of BC in CIS women was significantly elevated compared with controls (OR = 2.6, 95% CI: 1.5, 4.5). While women with CIS had a higher odds of development of BC compared to those without CIS, at 20-year post CIS diagnosis, more than 80% of them remained free of invasive BC. This low probability of developing invasive BC post CIS diagnosis does not support the notion that CIS of the breast is an obligate precursor lesion of invasive BC.

Citing Articles

Association between long-term use of calcium channel blockers (CCB) and the risk of breast cancer: a retrospective longitudinal observational study protocol.

Ho C, Thi Ha N, Youens D, Abhayaratna W, Bulsara M, Hughes J BMJ Open. 2024; 14(3):e080982.

PMID: 38458796 PMC: 10928765. DOI: 10.1136/bmjopen-2023-080982.


The OncoSim-Breast Cancer Microsimulation Model.

Yong J, Nadeau C, Flanagan W, Coldman A, Asakawa K, Garner R Curr Oncol. 2022; 29(3):1619-1633.

PMID: 35323336 PMC: 8947518. DOI: 10.3390/curroncol29030136.


Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors.

Christgen M, Cserni G, Floris G, Marchio C, Djerroudi L, Kreipe H Cancers (Basel). 2021; 13(15).

PMID: 34359596 PMC: 8345067. DOI: 10.3390/cancers13153695.


Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study.

Williams L, Casbas-Hernandez P, Nichols H, Tse C, Allott E, Carey L PLoS One. 2019; 14(1):e0211488.

PMID: 30682163 PMC: 6347264. DOI: 10.1371/journal.pone.0211488.


MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene.

Balatti V, Oghumu S, Bottoni A, Maharry K, Cascione L, Fadda P Head Neck Pathol. 2018; 13(3):344-354.

PMID: 30259272 PMC: 6684709. DOI: 10.1007/s12105-018-0971-x.